Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2019-12-24 Capital/Financing Update
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Subject to the approval of the members of the Company, the Board has recommended issue of Bonus equity shares ('Bonus shares') in the proportion of 2:1 i.e. 2 (Two) new fully paid-up equity ....
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to the stock exchange (BSE Limited) regarding the outcome of a Board Meeting held on December 24, 2019. It details the Board's approval of a bonus share issue, adoption of an employee stock option plan, and plans for a postal ballot to seek shareholder approval. The document includes specifics about the bonus issue ratio, record date, share capital pre- and post-bonus, and audited reserves backing the bonus issue. It is an announcement of corporate actions decided by the Board rather than a full financial report or earnings release. The focus is on informing shareholders and the market about Board decisions and upcoming shareholder voting, consistent with a Capital/Financing Update. It is not an Annual Report, Interim Report, Earnings Release, or Regulatory Filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5870 characters) and content support this classification with high confidence.
2019-12-24 English
Subject to members'' approval, the Board has: (a) approved issue of bonus shares Bonus in proportion of 2:1 (b) fixed Monday, February 3, 2020 as the Record Date to determine ....
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to the stock exchange (BSE Limited) reporting the outcome of a Board Meeting held on December 24, 2019. It details the Board's approval of a bonus share issue, adoption of an employee stock option plan, and plans for a postal ballot to seek shareholder approval. The document includes specifics about the bonus issue ratio, record date, share capital pre- and post-bonus, and reserves backing the bonus issue. It is an announcement of decisions made by the Board rather than a full financial report or detailed financial statements. The document is about corporate actions and approvals by the Board, not an annual or interim report, earnings release, or audit report. It fits the category of Capital/Financing Update (CAP) because it announces a proposed bonus share issue and related capital structure changes, which are financing activities. The document length (5870 characters) and content confirm it is not a mere report publication announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2019-12-24 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide ....
Regulatory Filings
2019-12-18 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about a scheduled meeting between company officials and investors/analysts. It references an investor presentation that is available on the exchange website but does not contain the presentation itself or any financial data. The document is an announcement of an upcoming investor interaction and the availability of a presentation, not the presentation or report itself. The document length is only 1853 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Investor Presentation (IP) announcements or related notices. However, since the document is primarily an intimation of the schedule of the meeting and the availability of the presentation elsewhere, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement under SEBI regulations and does not contain the presentation itself or detailed financial data.
2019-12-17 English
Fermenta Biotech Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on December 24, 2019, inter alia:1. To consider, approve and ....
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled for December 24, 2019, issued by the company to the stock exchange (BSE Limited). It informs about agenda items such as approval of ESOP Trust documents, amendments to the Employee Stock Option Plan, and recommendation of bonus equity shares. It also mentions the closure of the trading window in compliance with SEBI regulations. The document is a formal announcement of an upcoming board meeting and related compliance matters, not a report or detailed financial disclosure. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or meetings of the board of directors or senior management.
2019-12-17 English
In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company''s Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the 'Trading ....
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled for December 24, 2019, issued by the company to the stock exchange. It mentions agenda items such as approval of ESOP Trust documents, amendments to the Employee Stock Option Plan, and recommendation of bonus equity shares. It also includes a trading window closure notice in compliance with SEBI regulations. The document is a formal announcement informing about the upcoming Board Meeting and trading restrictions, not the actual meeting minutes or detailed management information. It does not contain financial data or detailed management reports. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting scheduling and related disclosures.
2019-12-17 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.